After adjustment, light physical activity significantly linked to lower mortality in cardiovascular-kidney-metabolic syndrome stages 2 to 4
THURSDAY, Jan. 8, 2026 (HealthDay News) — For individuals with cardiovascular-kidney-metabolic (CKM) syndrome stages 2 and above, light-intensity physical activity (PA), such as common everyday activities, is associated with a lower risk for all-cause mortality, according to a research letter published online Jan. 7 in the Journal of the American Heart Association.
Joseph Sartini, from Johns Hopkins University in Baltimore, and colleagues examined the association between light PA and all-cause mortality by CKM stage in a sample of 7,246 U.S. adults from the 2003 to 2006 National Health and Nutrition Examination Survey.
The researchers observed a modest correlation between light PA and moderate-to-vigorous physical activity (r = 0.34 to 0.43 depending on CKM stage). Median light PA was highest and lowest in CKM stage 0/1 and stage 4 (4.8 and 3.5 hours/day, respectively). In all stages, the median proportion of total active time spent performing light PA was ≥93.8 percent, and in CKM stages 3 and 4, it was ≥98.5 percent. During a median follow-up of 14.4 years, there were 80, 583, 565, and 571 deaths in stages 0/1, 2, 3, and 4, respectively (3.3, 10.5, 74.9, and 70.7 per 1,000 person-years, respectively). In CKM stages 2 to 4, light PA was significantly associated with lower mortality after adjustment. The relative risk for mortality was 14 to 20 percent lower with each one-hour increase. The inverse association between active time and mortality was strongest in stage 4 CKM syndrome, on an absolute scale.
“Light physical activity is an overlooked treatment tool that can help improve heart health for people with CKM syndrome,” Sartini said in a statement.
Two authors disclosed ties to the medical and health technology industries.
Dietary Nitrate From Beetroot Juice Promising for Pregnant Women With CKD
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death
Premature Menopause Linked to Increased Risk for Hypertension
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia
Food-Based Support Aids Type 2 Diabetes Outcomes
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA
Burden of Myocardial Dysfunction Elevated for Individuals With Psoriasis
2017 to 2022 Saw More Than Doubling in Use of GLP-1 Receptor Agonists